Board of Directors

Frederick Bart 

Non-Executive Chair

In 1985, Mr Bart was appointed the Managing Director of Textile Industries Australia The Group employed over 1,200 people and distributed product to many countries worldwide. The Company manufactured and distributed the majority of bed linen in Australia under brands like Sheridan and ACTIL The Company was sold in 1987.

In 1989, Mr Bart established and chairs a number of private companies under the umbrella of the Bart Group which covered hotels, retail, commercial and residential land development and technologies which still continue to operate. The Group today employs in excess of 1,000 people and is active in many local and overseas markets.

In 2001, Mr Bart became Chairman of Electro Optic Systems Holdings Limited (ASX: EOS). Since that time it has grown to be one of Australia’s premier defence companies with activities in many countries worldwide employing over 400 people and is currently included in the S&P/ASX 300.

In September 2000, Mr Bart became a director and Chairman of Audio Pixels Holdings Limited (ASX: AKP). Audio Pixels is developing the first digital speaker in the world and currently has a market capitalisation of over $600m.

In 2013, Mr Bart became Chairman and majority shareholder of Immunovative Therapies Limited, a private Israeli company involved in the manufacture of vaccines for the treatment of certain forms of cancer. The Company has undertaken trials in both collateral and liver cancers.

In March 2018, Mr Bart joined the Board of Weebit Nano Limited (ASX: WBT). Weebit is a developer of memory technology (1,000 X faster, 1,000 X more energy efficient and 100X higher endurance) than existing flash memory technologies.

In May 2020, Mr Bart was appointed to the Board of Noxopharm Limited (ASX: NOX).

Read more

Dr Gisela Mautner 

Chief Executive Officer and Managing Director

MD-PhD (TU-LMU Munich), MPH (Harvard), MBA (Kellogg), FACPE (Australia), AMCEOI, MAICD

Dr Mautner is an international business leader with significant experience developing and launching new pharmaceutical products, and delivering successful corporate strategies in highly competitive global markets.

After joining Noxopharm in 2019 as Chief Medical Officer, Gisela was appointed to the CEO and Managing Director roles in early 2022. Her focus is on leading the strategy for Noxopharm’s next stage of development, and the creation and out-licensing of drug assets in oncology and inflammatory disease.

In addition to serving on the Noxopharm Board, she is also a Non-Executive Director of Nyrada Inc, a US biotechnology company listed on the ASX, as well as a member of the Board of NFP Australian Ice Racing.

Before joining Noxopharm, Gisela spent more than 30 years in the medical sector, including leadership in global pharmaceutical organisations across multiple continents and therapeutic areas.

Having held senior positions at major companies including MSD (Merck), Bayer and Amgen, in roles encompassing operations, medical and scientific advisory, research and marketing, Gisela brings a deep understanding of the industry to Noxopharm.

Gisela has strong industry networks and served as President, Vice-President and Treasurer of the Australian Pharmaceutical Physicians Association (APPA) for many years, and is currently serving as Past-President. She is also the Australian delegate for the International Federation of Associations of Pharmaceutical Physicians (IFAPP), which connects the pharmaceutical industry globally.

Gisela’s leadership experience is founded on an education at some of the world’s highest-ranking institutions, with an MBA from the Kellogg School of Management at Northwestern University in Chicago, a Master of Public Health from Harvard, a PhD from Ludwig Maximilian University in Munich, and a Doctor of Medicine degree from Technical University in Munich. She is also a Member of the Australian Institute of Company Directors and the CEO Institute.

Read more

Peter Marks 

Non-Executive Director and Deputy Chairman

B.Econ; LL.B; Grad Dip. Comm.Law;  (all Monash Univ.) MBA (Scottish Business School, Edinburgh)

Peter has over 35 years’ experience in corporate advisory, and investment banking. Over the course of his long career, he has specialised in capital raising IPO's, cross border, M&A transactions, corporate underwriting and venture capital transactions for companies in Australia, the US and Israel. He has been involved in a broad range of transactions with a special focus in the life sciences, biotechnology, medical technology and high tech segments. Peter has served as both an Executive and Non-Executive Director of a number of different entities which have been listed on the ASX, Nasdaq and AIM markets.

Peter holds a Bachelor of Economics, Bachelor of Laws and a Graduate Diploma in Commercial Law from Monash University, Australia. He also holds an MBA from the University of Edinburgh, Scotland.

Alterity Therapeutics Limited (ASX: ATH) - since 29 July 2005  (formerly known as Prana Biotechnology Limited), Fluence Corporation Limited (ASX: FLC) (May 2015 – March 2020), Elsight Limited (ASX: ELS) since 9 January 2020 and Nyrada Inc. (ASX:NYR) since 16 January 2020.

Read more

Boris Patkin 

Non-Executive Director

BSc (Industrial Chem) MeSAFAA

Boris brings comprehensive market knowledge, thorough research and years of experience in investment markets & Business Consulting.

Boris’s experience lends itself to Financial & Investment advising but also as a business consultant to further enhance business opportunities in Medical technology & in sourcing other opportunities to enhance investments. Boris has worked extensively with Israeli companies to explore various opportunities in the Medical & disruptive technology space.

Boris has developed an in-depth understanding of industry trends and gained valuable insight into domestic and international markets. Boris has specialised in reconstruction of Companies, Investments &International trade

Boris has completed a Bachelor of Science (Industrial Chemistry). Currently a member of MeSAFAA & an Authorised Representative with Morgans Financial Ltd.

Read more

David Franks 

Company Secretary

B.Ec ( Finance and Accounting)

David is a Director and Principal of the Automic Group. He is a Chartered Accountant, Fellow of the Financial Services Institute of Australasia, Fellow of the Governance Institute of Australia, Justice of Peace and Registered Tax Agent, with over 20 years’ experience as a Director and Company Secretary of numerous publicly listed entities. He holds a Bachelor of Economics (Finance and Accounting) from Macquarie University. David is an experienced Company Secretary and Director of listed and unlisted public companies and is currently Company Secretary for the following ASX listed public companies: Aumake Limited, COG Financial Services Limited, Cogstate Limited, JCurve Solutions Limited, IXUP Limited, Noxopharm Limited, Nyrada Inc, White Energy Company Limited and ZIP Co Limited.

Read more